Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Kadmon Holdings Llc (KDMN)

Kadmon Holdings Llc (KDMN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 699,950
  • Shares Outstanding, K 171,137
  • Annual Sales, $ 5,100 K
  • Annual Income, $ -61,370 K
  • 60-Month Beta 1.30
  • Price/Sales 140.07
  • Price/Cash Flow N/A
  • Price/Book 5.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.13
  • Number of Estimates 3
  • High Estimate -0.13
  • Low Estimate -0.14
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +31.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.53 +15.72%
on 08/06/20
4.44 -8.00%
on 07/15/20
-0.13 (-2.97%)
since 07/10/20
3-Month
3.53 +15.72%
on 08/06/20
5.50 -25.73%
on 06/24/20
-0.68 (-14.36%)
since 05/12/20
52-Week
2.04 +100.25%
on 08/30/19
5.50 -25.73%
on 06/24/20
+1.63 (+66.73%)
since 08/12/19

Most Recent Stories

More News
Kadmon Provides Business Update and Reports Second Quarter 2020 Financial Results

/ Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2020.

KDMN : 4.09 (unch)
Kadmon Doses First Patient in Phase 1 Clinical Trial of KD033, an Anti-PD-L1/IL-15 Fusion Protein, in Adults with Metastatic or Locally Advanced Solid Tumors

NEW YORK, NY / ACCESSWIRE / June 23, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating KD033, an anti-PD-L1/IL-15 fusion...

FSNN : 0.0580 (-19.44%)
KDMN : 4.09 (unch)
Kadmon to Present at the Raymond James 2020 Virtual Human Health Innovation Conference

NEW YORK, NY / ACCESSWIRE / June 11, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Raymond James 2020...

KDMN : 4.09 (unch)
Kadmon Raises $50 Million in Gross Proceeds Through Its at-the-Market Facility

NEW YORK, NY / ACCESSWIRE / June 5, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that it has raised gross proceeds of $50.0 million through its At-The-Market (ATM) facility, including participation...

KDMN : 4.09 (unch)
Kadmon to Present at the Jefferies 2020 Virtual Global Healthcare Conference

NEW YORK, NY / ACCESSWIRE / May 27, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the Jefferies 2020 Virtual...

KDMN : 4.09 (unch)
Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease

ORRs of 73% and 74% with Belumosudil (KD025) 200 mg QD and 200 mg BID, Respectively

KDMN : 4.09 (unch)
Kadmon Provides Business Update and Reports First Quarter 2020 Financial Results

/ Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2020.

KDMN : 4.09 (unch)
MGTX : 14.26 (+2.89%)
Kadmon Announces Receipt of Final Meeting Minutes from FDA Following Pre-NDA Meeting for KD025 for the Treatment of cGVHD

- Kadmon on Track for NDA Submission for KD025 in Q4 2020 -

KDMN : 4.09 (unch)
Kadmon Announces Update on pre-NDA Meeting with FDA and Provides Business Update

NEW YORK, NY / ACCESSWIRE / March 13, 2020 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the Company held its pre-New Drug Application (NDA) meeting as scheduled with the U.S. Food and Drug...

KDMN : 4.09 (unch)
Kadmon Highlights Recent Progress and Reports Fourth Quarter and Full Year 2019 Financial Results

Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2019.

KDMN : 4.09 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Trade KDMN with:

Business Summary

Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology...

See More

Key Turning Points

2nd Resistance Point 4.32
1st Resistance Point 4.20
Last Price 4.09
1st Support Level 4.02
2nd Support Level 3.95

See More

52-Week High 5.50
Fibonacci 61.8% 4.18
Last Price 4.09
Fibonacci 50% 3.77
Fibonacci 38.2% 3.36
52-Week Low 2.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar